Pahr S1, Selb R2, Weber M3, Focke-Tejkl M3, Hofer G4, Dordić A4, Keller W4, Papadopoulos NG5, Giavi S5, Mäkelä M6, Pelkonen A6, Niederberger V2, Vrtala S1,Valenta R3.
- Shawn L. Ralston, MD, FAAP,
- Allan S. Lieberthal, MD, FAAP,
- H. Cody Meissner, MD, FAAP,
- Brian K. Alverson, MD, FAAP,
- Jill E. Baley, MD, FAAP,
- Anne M. Gadomski, MD, MPH, FAAP,
- David W. Johnson, MD, FAAP,
- Michael J. Light, MD, FAAP,
- Nizar F. Maraqa, MD, FAAP,
- Eneida A. Mendonca, MD, PhD, FAAP, FACMI,
- Kieran J. Phelan, MD, MSc,
- Joseph J. Zorc, MD, MSCE, FAAP,
- Danette Stanko-Lopp, MA, MPH,
- Mark A. Brown, MD,
- Ian Nathanson, MD, FAAP,
- Elizabeth Rosenblum, MD,
- Stephen Sayles III, MD, FACEP, and
- Sinsi Hernandez-Cancio, JD
ABSTRACT
This guideline is a revision of the clinical practice guideline, “Diagnosis and Management of Bronchiolitis,” published by the American Academy of Pediatrics in 2006. The guideline applies to children from 1 through 23 months of age. Other exclusions are noted. Each key action statement indicates level of evidence, benefit-harm relationship, and level of recommendation. Key action statements are as follows:
